Dr. Berinstein on Combination Treatments for High-Risk and Recurrent Follicular Lymphoma

Neil L. Berinstein, MD
Published Online: Friday, Jun 16, 2017



Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.

High-dose therapy and stem cell transplants with immunotherapy is a very valuable treatment for patients with high-risk or recurrent follicular lymphoma, according to Berinstein.

Many patients relapse after their first initial frontline treatment for follicular lymphoma within the first year. However, due to this treatment, patients are now going without requiring further treatment for a median of 8 years, explains Berinstein.
 


Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.

High-dose therapy and stem cell transplants with immunotherapy is a very valuable treatment for patients with high-risk or recurrent follicular lymphoma, according to Berinstein.

Many patients relapse after their first initial frontline treatment for follicular lymphoma within the first year. However, due to this treatment, patients are now going without requiring further treatment for a median of 8 years, explains Berinstein.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Optimizing Treatment and Management of Soft Tissue Sarcoma in Community OncologyNov 30, 20171.5
Community Practice Connections™: 1st Annual European Congress on Immunotherapies in Cancer™Dec 13, 20171.5
Publication Bottom Border
Border Publication
x